PHAT

Phathom Pharmaceuticals, Inc.

7.25 USD

Last updated Dec 4, 06:33 UTC

Yesterday HIGH

$7.32

Yesterday LOW

$6.9

52w HIGH

$17.02

52w LOW

$5.84

EPS

-0.76

PE

-9.54

Next Earnings

Feb 27, 2024

Overview News Insider Transactions Government Trades

Phathom Pharmaceuticals, Inc. stock is down -16.95% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. 100% of analysts rate it a buy.

Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

phathompharma.com

Vandana Singh

Wed May 24, 2023

Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity
Happy Mohamed

Tue May 23, 2023

CORRECTION: Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Intends To Grant The Underwriters A 30-Day Option To Purchase Up To An Additional 15% Of The Total Number Of The Shares Of Its Common Stock Offered

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell,
Benzinga Newsdesk

Tue May 23, 2023

Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
Benzinga Newsdesk

Tue May 23, 2023

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application To FDA

The company has resubmitted its New Drug Application (NDA) for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also
Benzinga Insights

Thu May 11, 2023

Analyst Expectations for Phathom Pharmaceuticals's Future
Benzinga Insights

Thu May 11, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
richadhand@benzinga.com

Thu May 11, 2023

Evercore ISI Group Upgrades Phathom Pharmaceuticals to Outperform

Evercore ISI Group analyst Umer Raffat upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from In-Line to Outperform.
Happy Mohamed

Wed May 10, 2023

Phathom Pharmaceuticals Q1 EPS $(0.89) Beats $(1.26) Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.26) by 29.37 percent. This is a 16.82 percent increase over losses of $(1.07) per
richadhand@benzinga.com

Wed Apr 19, 2023

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $23 Price Target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $23 price target.
Lisa Levin

Wed Apr 12, 2023

Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Needham

Fri Nov 10, 04:14

buy

confirm

Advanced Data Unlock

Henderson Molly, CFO and CBO

Mon Nov 20, 2023

PHAT Recent Insider Trades and Stock Chart

2,127 shares sold
Parikh Asit, Director

Mon Nov 6, 2023

PHAT Recent Insider Trades and Stock Chart

1,000 shares bought
Parikh Asit, Director

Tue Nov 7, 2023

PHAT Recent Insider Trades and Stock Chart

4,000 shares bought
Parikh Asit, Director

Wed Nov 8, 2023

PHAT Recent Insider Trades and Stock Chart

2,500 shares bought